Intarcia Therapuetics has been backed by the Bill and Melinda Gates Foundation on a new technology that could prevent the spread of infection

HIV remains one of the world’s most dangerous diseases, and despite plenty of 21st century medical breakthroughs, we haven’t been able to effectively combat the STD beyond reducing its effects or taking preventative measures against it. Despite advancements in gene editing through the use of CRISPR/Cas9, and other such tools, we still haven’t reached a point where we can safely say that we’ve defeated the virus once and for all. In response to the growing body of actionable research surrounding the virus, the Bill and Melinda Gates Foundation has recently announced a $140 million USD investment in an Intarcia Therapuetics program working to develop an implant embedded beneath the skin which will work to administer steady streams of anti-HIV drugs to infected bodies over the course of six to 12 months.

PSFK provides access to this article and every report, case-study, interview, and analysis that we publish for our members. PSFK Professional Membership also unlocks access to customized research assistance and our database of over 100,000 insights on innovation trends spanning across eight industry sectors—from culture and brand to retail and customer experience.
Already a subscriber? Log in.